RS Oncology Announces Positive Data from a Phase 1 Clinical Trial of RSO-021, a First-in-Class Therapeutic for Malignant Pleural Mesothelioma
RS Oncology Data for Novel Treatment of Aggressive Cancers Selected for an Oral Presentation at ASCO Annual Meeting
RS Oncology Announces First Patient Dosed in Phase 2 Study Investigating RSO-021